1035374-20-9

Basic information

• Product Name: 3-Aminocyclobutanone hydrochloride
• Synonyms: 3-Aminocyclobutanone hydrochloride;3-aminocyclobutanone hydr...;3-AMinocyclobutanone HCl;Cyclobutanone, 3-amino-, hydrochloride;3-aminocyclobutan-1-one hydrochloride
• CAS NO: 1035374-20-9
• Molecular Formula: C₄H₇NO*ClH
• Molecular Weight: 122
• Mol File: 1035374-20-9.mol

Chemical Properties

• Melting Point: 127-130 °C (decomp)
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-Aminocyclobutanone hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Aminocyclobutanone hydrochloride(1035374-20-9)
• EPA Substance Registry System: 3-Aminocyclobutanone hydrochloride(1035374-20-9)

Safety Data

• Hazardous Substances Data: 1035374-20-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Aminocyclobutanone hydrochloride is used as a synthetic intermediate for the preparation of aminocyclopentenyland aminocyclobutylphosphinic acids. These compounds act as γ-aminobutyric acid (GABA) ρ1 receptor antagonists, which are important in the development of medications targeting neurological disorders.
Additionally, 3-Aminocyclobutanone hydrochloride is used as a synthetic intermediate for the preparation of pyrrolopyrazine derivatives. These derivatives are selective spleen tyrosine kinase (Syk) inhibitors, which have potential applications in the treatment of autoimmune diseases and inflammatory conditions.

InChI:InChI=1S/C4H7NO.ClH/c5-3-1-4(6)2-3;/h3H,1-2,5H2;1H

Upstream product

• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 130233-77-1 3-oxocyclobutane-1-carbonyl chloride 

Downstream Products

• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1449278-40-3 tert-butyl (7-(3-fluorophenyl)-4-((3-oxocyclobutyl)carbamoyl)isoquinolin-1-yl)carbamate 

Relevant articles and documents

Truce–Smiles Rearrangements by Strain Release: Harnessing Primary Alkyl Radicals for Metal-Free Arylation

The ring-opening of 3-aminocyclobutanone oximes enables easy generation of primary alkyl radicals, capable of undergoing an unprecedented strain-release, desulfonylative radical Truce–Smiles rearrangement, providing divergent access to valuable 1,3 diamin

N-ACYLETHANOLAMINE HYDROLYZING ACID AMIDASE (NAAA) INHIBITORS AND THEIR USE THEREOF

A compound is represented as Formula I, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Compounds of Formula I are inhibitors of N-acylethanolamine hydrolyzing acid amidase (NAAA). The present technology is directed to compounds, compositions, and methods to inhibit N-acylethanolamine hydrolyzing acid amidase and to treat N-acylethanolamine hydrolyzing acid amidase mediated conditions in a subject.

ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES

The invention provides novel compounds having the general formula(I) wherein A, R1 and R2 are as described herein, compositions including the compounds and use of the compounds for inhibiting angiogenesis by inhibition of MAP4K4.

Novel γ-aminobutyric acid ρ1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships

γ-Aminobutyric acid (GABA) analogues based on 4-amino-cyclopent-1- enyl phosphinic acid (34-42) and 3-aminocyclobutane phosphinic acids (51, 52, 56, 57) were investigated in order to obtain selective homomeric ρ1 GABAC receptor antagonists. The effect of the stereochemistry and phosphinic acid substituent of these compounds on potency and selectivity within the GABA receptor subtypes was investigated. Compounds of high potency at GABAC ρ1 receptors (36, KB = 0.78 μM) and selectivity greater than 100 times (41, KB = 4.97 μM) were obtained. The data obtained was analyzed along with the known set of GABAC ρ1 receptor-ligands, leading to the development of a pharmacophore model for this receptor, which can be used for in silico screening.